JPRN-UMIN000047221招募中未知
Effectiveness of once-weekly Semaglutide in patients with type 2 diabetes undergoing hemodialysis. - Effectiveness of once-weekly Semaglutide in patients with type 2 diabetes undergoing hemodialysis.
Sohbudai Nieren Clinic0 个研究点目标入组 8 人开始时间: 2022年3月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 8
研究概览
简要总结
weekly semaglutide is a safe and effective option for glycemic control and weight management in obese people with T2D on HD.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who refused to participate in this research.
研究者
相似试验
已完成
3 期
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)ObesityDiabetes Mellitus, Type 2NCT05514535Novo Nordisk A/S573
进行中(未招募)
1 期
Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetesDiabetes Mellitus, Type 2MedDRA version: 17.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2013-004392-12-ROovo Nordisk A/S1,082
进行中(未招募)
不适用
Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2013-004392-12-NLovo Nordisk A/S1,047
已完成
3 期
Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetesdiabetesNL-OMON41148ovo Nordisk15
已完成
3 期
A trial to evaluate the Efficacy and safety of semaglutide given once weekly versus insulin glargine given once daily as add on to metformin with or without sulphonylurea in subjects with type 2 diabetes ,who have not yet been treated with insulin.CTRI/2014/09/005033ovo Nordisk AS83
